C4 Therapeutics Doses First Patient in Key Phase 1b Multiple Myeloma Trial
CCCC has more than doubled off its 52-week low of $1.085.
Summary
C4 Therapeutics announced the dosing of the first patient in its Phase 1b trial evaluating cemsidomide in combination with elranatamab (ELREXFIO®) for relapsed/refractory multiple myeloma. This trial is a significant step in the company's pipeline, leveraging a clinical collaboration supply agreement with Pfizer from October 2025, where Pfizer provides the FDA-approved elranatamab. For a clinical-stage biopharmaceutical company, initiating a new phase of a clinical trial, especially with a major pharma partner and an FDA-approved combination, is a material de-risking event and a positive advancement for its lead candidate. The company's strong cash position, extended through 2028 by a recent $116.9 million offering, supports this development. Investors will be watching for Phase 1b data, anticipated in mid-2027, and further updates on cemsidomide's broader development strategy, including plans for other combination agents in mid-2026.
At the time of this announcement, CCCC was trading at $2.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $243.9M. The 52-week trading range was $1.09 to $3.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.